Ionis Pharmaceuticals (IONS) to Announce Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is anticipated to release its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect Ionis Pharmaceuticals to announce earnings of ($1.0914) per share and revenue of $189.0550 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.29. Ionis Pharmaceuticals had a negative return on equity of 58.65% and a negative net margin of 30.91%.The company had revenue of $246.09 million during the quarter, compared to analysts’ expectations of $195.56 million. During the same period last year, the business posted ($0.93) earnings per share. The firm’s revenue was up 86.4% compared to the same quarter last year. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ionis Pharmaceuticals Stock Performance

IONS opened at $53.39 on Wednesday. The firm’s 50-day moving average price is $72.82 and its 200-day moving average price is $75.99. The company has a market cap of $8.82 billion, a P/E ratio of -25.79 and a beta of 0.36. Ionis Pharmaceuticals has a 52-week low of $40.03 and a 52-week high of $86.74. The company has a quick ratio of 4.09, a current ratio of 4.10 and a debt-to-equity ratio of 2.75.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on IONS shares. Raymond James Financial set a $87.00 target price on Ionis Pharmaceuticals in a research report on Thursday, July 9th. Canaccord Genuity Group reduced their price target on shares of Ionis Pharmaceuticals from $110.00 to $95.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Needham & Company LLC lowered their target price on Ionis Pharmaceuticals from $105.00 to $86.00 and set a “buy” rating on the stock in a research note on Thursday, July 9th. Bank of America lifted their price target on Ionis Pharmaceuticals from $100.00 to $111.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Finally, The Goldman Sachs Group increased their target price on shares of Ionis Pharmaceuticals from $74.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 24th. Eighteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.90.

Insiders Place Their Bets

In related news, EVP Holly B. Kordasiewicz sold 362 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $84.30, for a total value of $30,516.60. Following the completion of the sale, the executive vice president owned 22,096 shares of the company’s stock, valued at approximately $1,862,692.80. This represents a 1.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Eugene Schneider sold 26,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $81.05, for a total transaction of $2,107,300.00. Following the sale, the executive vice president owned 77,114 shares of the company’s stock, valued at approximately $6,250,089.70. The trade was a 25.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 233,163 shares of company stock worth $18,316,551. 1.81% of the stock is currently owned by company insiders.

Institutional Trading of Ionis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Brown Brothers Harriman & Co. purchased a new stake in Ionis Pharmaceuticals in the fourth quarter valued at approximately $27,000. Quarry LP acquired a new position in Ionis Pharmaceuticals during the third quarter worth approximately $38,000. Johnson Financial Group Inc. purchased a new stake in Ionis Pharmaceuticals in the third quarter valued at approximately $44,000. Los Angeles Capital Management LLC purchased a new stake in Ionis Pharmaceuticals in the 4th quarter valued at $52,000. Finally, Summit Securities Group LLC acquired a new stake in Ionis Pharmaceuticals during the 4th quarter worth $59,000. 93.86% of the stock is currently owned by hedge funds and other institutional investors.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.